Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
Healthcare
$61.99 -1.39%
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
52W Low $13.09High $35.66
Volume 0.48M
Average 0.43M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$10.52M
FY 2025 · Annual
+986.1% YoYInvesting Cash Flow
-$333,000.00
FY 2025 · Annual
Financing Cash Flow
$815,000.00
FY 2025 · Annual
-97.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| Deferred Income Tax | (546K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M |
| Change in Working Capital | (6.21M) | 7.66M | 3.53M | (698K) | (859K) |
| Accounts Receivables | (5.42M) | 3.62M | (1.56M) | (3.12M) | (6.4M) |
| Inventory | 692K | (7K) | (354K) | (1.31M) | (5.88M) |
| Accounts Payables | (570K) | (8K) | 53K | 2.32M | 6.81M |
| Other Working Capital | (910K) | 4.06M | 5.39M | 1.41M | 4.61M |
| Other Non-Cash Items | 148K | 189K | 184K | 1.18M | 6.43M |
| Operating Cash Flow | (4.72M) | 4.82M | 6.82M | 969K | 10.52M |
| Capital Expenditures | (3.26M) | (2.79M) | (775K) | (26K) | (333K) |
| Acquisitions (Net) | 700K | 0 | 0 | (30M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (2.75M) | 0 | (9.99M) | 0 |
| Investing Cash Flow | (2.56M) | (2.79M) | (775K) | (40.01M) | (333K) |
| Debt Repayment | (150K) | (385K) | (1.16M) | 24.15M | 0 |
| Common Stock Issued | 541K | 0 | 0 | 8.19M | 598K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 251K | 198K | 248K | 217K |
| Financing Cash Flow | 391K | (134K) | (957K) | 32.59M | 815K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.89M) | 1.9M | 5.08M | (6.45M) | 11.01M |
| Free Cash Flow | (7.98M) | 2.03M | 6.04M | 943K | 10.19M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$4.6M
+ D&A$4.0M
+ Stock-Based Comp$5.5M
+ Deferred Tax$0
- Working Capital-$859.0K
+ Other Non-Cash$6.4M
= Operating Cash Flow$10.5M
- Capex-$333.0K
= Free Cash Flow$10.2M
Analysis
FY2025 free cash flow is $10.2M. FCF conversion is -221.5% of net income. Operating cash flow was $10.5M, with capex of -$333.0K. The largest bridge item is Other Non-Cash at $6.4M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does ETON generate free cash flow?
Eton Pharmaceuticals, Inc. (ETON) generated $10.19M of free cash flow in fiscal 2025.
How much operating cash flow does ETON produce?
Operating cash flow was $10.52M, before capital expenditures of $333,000.00.
Continue the stock analysis
Jump to another research area for this company.